



Essilor Announces Exclusive and Global License Agreement with High Performance Optics

Essilor complements its prevention patent portfolio

(Charenton le Pont –France-, 2 April 2013) – Essilor, the world leader in ophthalmic optics, has signed an exclusive and global license agreement with High Performance Optics (HPO) that complements its existing patent and technologies portfolio. This licence agreement will allow Essilor to continue to focus on products with correction and preventive benefits and to roll out its robust portfolio of patented products around the world. HPO is a company focused on human retinal protection from blue light.

Essilor continues to strengthen its mission of helping the world see better by reaching the 4.2 billion people worldwide who need vision correction. Recently named as one of the Most Innovative Companies by Forbes, Essilor builds on its history of product innovation not only by providing quality vision correction, but also by providing products with preventive benefits for the wearer.

As a result of dedicated R&D and innovation processes, Essilor currently has around 5600 patents throughout the world that are a driving force behind its strategy.

Press contact: Maïlis Thiercelin
+33 1 49 77 45 02 – maïlis.thiercelin@essilor.com

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its corporate mission is to enable everyone around the world to access lenses that meet his or her unique vision requirements. To support this mission, the Company allocates more than €150 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Essilor's flagship brands are Varilux[®], Crizal[®], Definity[®], Xperio[®], Optifog[™] and Foster Grant[®]. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of approximately €5 billion in 2012 and employs around 50,700 people in some 100 countries. It operates 22 plants, more than 400 prescription laboratories and edging facilities, as well as several research and development centers around the world.

For more information, please visit www.essilor.com.

The Essilor share trades on the NYSE Euronext Paris market and is included in the EuroStoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.